Frequency and significance of antibodies to cyclic citrullinated peptide in type 1 autoimmune hepatitis

References

• Czaja AJ. Autoantibodies in autoimmune liver disease. Adv Clin Chem 2005; 40: 127–164
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors in type 1 autoimmune hepatitis. Am J Gastroenterol 2002; 97: 413–419
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Significance of HLA DR4 in type I autoimmune hepatitis. Gastroenterology 1993; 105: 1502–1507
   PubMed Web of Science ®Google Scholar
• Fusconi M, Vannini A, Dall'Aglio AC, Pappas G, Cassani F, Ballardini G, Frisoni M, Grassi A, Bianchi FB, Zauli D. Anti-cyclic citrullinated peptide antibodies in type 1 autoimmune hepatitis. Aliment Pharmacol Ther 2005; 22: 951–955
   PubMed Web of Science ®Google Scholar
• Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallman G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48: 2701–2705
   PubMedGoogle Scholar
• van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, Toes RE, Huizinga TW. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study. Arthritis Rheum 2004; 50: 709–715
   PubMed Web of Science ®Google Scholar
• Raza K, Breese M, Nightingale P, Kumar K, Potter T, Carruthers DM, Situnayake D, Gordon C, Buckley CD, Salmon M, Kitas GD. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol 2005; 32: 231–238
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006; 43: 532–538
   PubMed Web of Science ®Google Scholar
• Kroot EJ, de Jong BAW, van Leeuwen MA, Swinkles H, van den Hoogen FHJ, van't Hof M, van de Putte LB, van Rijswijk MH, van Venrooij WJ, van Riel PL. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000; 43: 1831–1835
   PubMed Web of Science ®Google Scholar
• Vossenaar ER, van Venrooij WJ. Anti-CCP antibodies, a highly specific marker for (early) rheumatoid arthritis. Clin Appl Immunol Rev 2004; 4: 239–262
   Google Scholar
• van der Helm-van Mill AHM, Verpoort KN, Breedveld FC, Toes REM, Huizinga TWJ. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005; 7: R949–R958
   Web of Science ®Google Scholar
• Vallbracht I, Helmke K. Additional diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Autoimmunity Rev 2005; 4: 389–394
   PubMed Web of Science ®Google Scholar
• Vossenaar ER, Nijenhuis S, van Helsen MM, van der Heijden A, Senshu T, van den Berg WB, van Venrooij WJ, Joosten LA. Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum 2003; 48: 2489–2500
   PubMed Web of Science ®Google Scholar
• Lundberg K, Nijenhuis S, Vossenaar ER, Palmblad K, van Ventooij WJ, Klareskog L, Zendman AJ, Harris HE. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther 2005; 7: R458–R467
   PubMed Web of Science ®Google Scholar
• Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WGE, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston ALWF, Fainboim L, Heathcote J, Homberg J-C, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RNM, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Buschenfelde K-H, Mieli-Vergani G, Nakanuma Y, Nishioka M, Penner E, Porta G, Portmann BC, Reed WD, Rodes J, Schalm SW, Scheuer PJ, Schrumpf E, Seki T, Toda G, Tsuji T, Tygstrup N, Vergani D, Zeniya M. International Autoimmune Hepatitis Group report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929–938
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002; 36: 479–497
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Manns MP. The validity and importance of subtypes of autoimmune hepatitis: A point of view. Am J Gastroenterol 1995; 90: 1206–1211
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–324
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996; 24: 1068–1073
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis. Dig Dis Sci 1997; 42: 1688–1696
   PubMed Web of Science ®Google Scholar
• Homburger HA, Cahen YD, Griffiths J, Jacob GL. Detection of antinuclear antibodies. Comparative evaluation of enzyme immunoassay and indirect immunofluorescence methods. Arch Pathol Lab Med 1998; 122: 993–999
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992; 103: 1290–1295
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA. Sensitivity, specificity and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993; 105: 1824–1832
   PubMed Web of Science ®Google Scholar
• DiMagno EP, Corle D, O'Brien JF, Masnyk IJ, Go VLW, Aamodt R. Effect of long-term freezer storage, thawing, and refreezing on selected constituents of serum. Mayo Clin Proc 1989; 64: 1226–1234
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease (CALD): Correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981; 80: 687–692
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Shums Z, Norman GL. Nonstandard antibodies as prognostic markers in autoimmune hepatitis. Autoimmunity 2004; 37: 195–201
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 1993; 18: 816–822
   PubMed Web of Science ®Google Scholar
• Vossenaar ER, Zendman AJW, vanVenrooij WJ, Pruijn G. PAD, a growing family of citrullinating enzymes: Genes, features and involvement in disease. Bioessays 2003; 25: 1106–1118
   PubMed Web of Science ®Google Scholar
• Neubauer K, Knittel T, Armbrust T, Ramadori G. Accumulation and cellular localization of fibrinogen/fibrin during short-term and long-term rat liver injury. Gastroenterology 1995; 108: 1124–1135
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Dos Santos RM, Porto A, Santrach PJ, Moore SB. Immune phenotype of chronic liver disease. Dig Dis Sci 1998; 43: 2149–2155
   PubMed Web of Science ®Google Scholar
• Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247–2250
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004; 40: 644–650
   Web of Science ®Google Scholar
• Irigoyen P, Lee AT, Wener MH, Li W, Kern M, Batliwalla F, Lum RF, Massarotti E, Weisman M, Bombardier C, Remmer EF, Kastner DL, Seldin MF, Criswell LA, Gregersen PK. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis. Contrasting effects of HLA-DR3 and the shared epitope alleles. Arthritis Rheum 2005; 52: 3813–3818
   PubMed Web of Science ®Google Scholar
• Linn-Rasker SP, van der Helm-van Mil AH, Van Gaalen FA, Kloppenburg M, de Vries R, le Cessie S, Breedveld FC, Toes RE, Huizinga TW. Smoking is a risk factor for anti-CCP antibodies only in RA patients that carry HLA-DRB1 shared epitope alleles. Ann Rheum Dis 2006; 65: 366–371
   PubMed Web of Science ®Google Scholar
• Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R. Susceptibility to autoimmune chronic active hepatitis: Human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991; 13: 701–706
   PubMed Web of Science ®Google Scholar